Synthesis and biological evaluation of prostaglandin-F alkylphosphinic acid derivatives as bone anabolic agents for the treatment of osteoporosis

Journal of Medicinal Chemistry

Volumn 44, Issue 24, 2001, Pages 4157-4169

  Soper, D L ^a   Milbank, J B J ^b   Mieling, G E ^a   Dirr, M J ^a   Kende, A S ^b   Cooper, R ^a   Jee, W S S ^c   Yao, W ^c   Jian Liang Chen, ^c   Bodman, M ^a   Lundy, M W ^a   De, B ^a   Stella, M E ^a   Ebetino, F H ^a   Wang, Y ^a   Delong, M A ^a   Wos, J A ^a  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 DECARBOXY 2 (4 METHYLPHOSPHINICO) 16 PHENOXYTETRANORPROSTAGLANDIN F2 ALPHA; ALKYL GROUP; ANABOLIC AGENT; CARBOXYLIC ACID; PHOSPHINIC ACID DERIVATIVE; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; FEMUR; MOLECULAR MODEL; MOUSE; NONHUMAN; OSTEOPOROSIS; OVARIECTOMY; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; BINDING, COMPETITIVE; BONE AND BONES; BONE DENSITY; COS CELLS; DENSITOMETRY, X-RAY; DINOPROST; FEMALE; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; OSTEOPOROSIS; OVARIECTOMY; PHOSPHINIC ACIDS; PROSTAGLANDINS F, SYNTHETIC; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PROSTAGLANDIN; STRUCTURE-ACTIVITY RELATIONSHIP; TOMOGRAPHY, X-RAY COMPUTED; TRANSFECTION;

EID: 0035935669     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm010264b     Document Type: Article

References (49)

1. Emerging therapies for osteoporosis
2. How many women have osteoporosis now?
3. The future of hip fractures in the United States. Numbers, costs, and potential effects in postmenopausal estrogen
4. New approaches to the treatment of osteoporosis
5. Oral bisphosphonates in the treatment of osteoporosis: A review
6. Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment
7. Skeletal effects of estrogen
8. In search of optimal long-term female hormone replacement: The potential of selective estrogen receptor modulators
9. Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone (1-34): Kinetics and biochemical response in estrogenized osteoporotic patients
10. Comparison of bone formation responses to parathyroid hormone (1-34), (131), and (2-34) in mice
11. 2 on bone balance and remodelling in osteoporosis
12. Cortical hyperostosis following long-term administration of prostaglandin E-1 in infants with cyanotic congential heart disease
13. 2 in rapidly growing rats: Depressed longitudinal and radial growth and increased metaphyseal hard tissue mass
14. 2α on the skeleton of osteopenic ovariectomized rats
15. The in vivo anabolic actions of prostaglandins in bone
16. 2 increases bone strength in intact rats and ovariectomized rats with established osteoporosis
17. 2
18. 1α analogues as potent and selective ligands for the human FP receptor
19. 1α sulfonamides: Potential treatments for osteoporosis
20. Automated modeling of the transmembrane region of G-coupled protein receptor by Swiss-model
21. 2 receptor allows discrimination between agonist and antagonist binding sites
22. Identification of critical functional groups within binding pockets of G-protein-coupled receptors
23. Synthesis and in vitro evaluation of human FP-receptor selective prostaglandin analogues
24. 2α
25. A practical alternative to the Hundsdieker reaction
26. The invention of new radical chain reactions. Part VIII. Radical chemistry of thiohydroxamic esters: A new method for the generation of carbon radicals from carboxylic acids
27. Studies with trialkylsilyltriflates: New syntheses and applications
28. Phenyl substituted prostaglandin analogues for glaucoma treatment
29. Phenyl-substituted prostaglandins: Potent and selective antiglaucoma agents
30. 2α isopropyl ester: Potential antiglaucoma agents
31. 2
32. 3PBr-Br geometry
33. Synthesis and biological activity of carboxyl-terminus modified prostaglandin analogues
34. N-(methanesulfonyl)-16-phenoxyprostaglandincarboxamides: Tissue-selective uterine stimulants
35. Three-dimensional microimaging (MRμI and μCT), finite element modeling, and rapid prototyping provide unique insights into bone architecture in osteoporosis
36. Structure-based design and synthesis of phosphinate isosteres of phosphotyrosine for incorporation in Grb2-SH2 domain inhibitors. Part 1
37. Structure-based design and synthesis of phosphinate isosteres of phosphotyrosine for incorporation in Grb2-SH2 domain inhibitors. Part 2
38. Bone histomorphometry: Standardization of nomenclature, symbols and units. Report of the ASBMR Histomorphometry Committee
39. Relationships between surface, area, and thickness of iliac trabecular bone in aging and in osteoporosis
40. Histomorphometric assay of the growing long bone